Efficacy of Trimebutine Maleate in the Treatment of Functional Dyspepsia in Childhood

  • Alexander A Nijevitch Bashkortostan State Medical University
  • Elsa N Akhmadeeva Bashkortostan State Medical University
  • Valery U Sataev Bashkortostan State Medical University
  • Bulat Idrisov Bashkortostan State Medical University
Keywords: Functional dyspepsia, Trimebutine, Opioid agonist, Dyspepsia

Abstract

Peripheral μ-, k- and δ-opioid agonist trimebutine maleate is considered to be an effective therapeutic drug for the treatment of functional gastrointestinal disorders. Ninety-two paediatric outpatients (12- 17 year-old) suffering from functional dyspepsia (epigastric pain and meal-induced dyspeptic symptoms) were enrolled in a prospective openlabel study. For ethical reasons, no placebo group was included. Patients were treated with trimebutine maleate (200 mg three times daily). After a 3-week treatment there was a significant decrease in scores of epigastric pain (p<0.05), postprandial fullness (p<0.05), early satiety (p<0.05), nausea (p<0.05) and belching (p<0.05). The treatment regimen was well tolerated and demonstrated a good compliance. In conclusion, we postulate that trimebutine maleate is an effective medication for relief of main symptoms associated with functional dyspepsia syndrome in childhood. Because of the limited data on therapeutic interventions in functional dyspepsia in childhood and increasing demand for therapies to treat this disorder, further evaluation of the efficacy of trimebutine treatment for children is certain.

DOI: http://dx.doi.org/10.3126/jnps.v33i2.7229  

J Nepal Paediatr Soc. 2013; 33(2):158-162

Downloads

Download data is not yet available.
Abstract
1187
PDF
1378

Author Biography

Alexander A Nijevitch, Bashkortostan State Medical University
Assistant Professor, Chair of Paediatrics
Published
2013-10-07
How to Cite
Nijevitch, A., Akhmadeeva, E., Sataev, V., & Idrisov, B. (2013). Efficacy of Trimebutine Maleate in the Treatment of Functional Dyspepsia in Childhood. Journal of Nepal Paediatric Society, 33(2), 158-162. https://doi.org/10.3126/jnps.v33i2.7229
Section
Novel Therapy